EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: Another piece to the puzzle

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1370-1371

  Fornaro, L ^a   Crea, F ^a   Masi, G ^a   Paolicchi, E ^a   Loupakis, F ^a   Graziano, F ^b   Salvatore, L ^a   Ronzoni, M ^c   Ricci, V ^c   Cremolini, C ^a   Schirripa, M ^a   Danesi, R ^a   Falcone, A ^a  

^a UNIVERSITY OF PISA   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; VASCULOTROPIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; DRUG EFFICACY; EZH2 GENE; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LETTER; METASTASIS; MONOTHERAPY; ONCOGENE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VASCULARIZATION;

EID: 84860436211     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds031     Document Type: Letter

References (4)

1. Crea F, Fornaro L, Paolicchi E et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann Oncol 2012; 23: 1207-1213.
2. Crea F, Paolicchi E, Marquez VE, Danesi R. Polycomb genes and cancer: time for clinical application? Crit Rev Oncol Hematol 2011 Nov 21 [epub ahead of print].
3. Lu C, Han HD, Mangala LS et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010; 18: 185-197.
4. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072.